A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQ as a Disease-Modifying Therapy in Parkinson's Disease
Identifieur interne : 002828 ( Main/Merge ); précédent : 002827; suivant : 002829A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQ as a Disease-Modifying Therapy in Parkinson's Disease
Auteurs : Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande]Source :
- Movement disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double-blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000950
- to stream PascalFrancis, to step Curation: 002369
- to stream PascalFrancis, to step Checkpoint: 000C41
Links to Exploration step
Pascal:10-0413289Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQ as a Disease-Modifying Therapy in Parkinson's Disease</title>
<author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurology Department, Auckland Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Auckland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antipodean Pharmaceuticals</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Antipodean Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antipodean Pharmaceuticals</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Antipodean Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch Hospital</s1>
<s2>Christchurch</s2>
<s3>NZL</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Christchurch</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Medicine, Neurology Research Centre and University of Queensland Clinical School, Royal Brisbane & Women's Hospital</s1>
<s2>Brisbane</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Brisbane</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Neurology, Westmead Hospital, Sydney Medical School, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Chemistry Department, University of Otago</s1>
<s2>Dunedin</s2>
<s3>NZL</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Dunedin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Medical Research Council Mitochondrial Biology Unit</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Medical Research Council Mitochondrial Biology Unit</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antipodean Pharmaceuticals</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Antipodean Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0413289</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0413289 INIST</idno>
<idno type="RBID">Pascal:10-0413289</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000950</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002369</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000C41</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Snow B:a:double:blind</idno>
<idno type="wicri:Area/Main/Merge">002828</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQ as a Disease-Modifying Therapy in Parkinson's Disease</title>
<author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurology Department, Auckland Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Auckland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antipodean Pharmaceuticals</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Antipodean Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antipodean Pharmaceuticals</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Antipodean Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch Hospital</s1>
<s2>Christchurch</s2>
<s3>NZL</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Christchurch</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Medicine, Neurology Research Centre and University of Queensland Clinical School, Royal Brisbane & Women's Hospital</s1>
<s2>Brisbane</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Brisbane</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Neurology, Westmead Hospital, Sydney Medical School, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Chemistry Department, University of Otago</s1>
<s2>Dunedin</s2>
<s3>NZL</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Dunedin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Medical Research Council Mitochondrial Biology Unit</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Medical Research Council Mitochondrial Biology Unit</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Antipodean Pharmaceuticals</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
<wicri:noRegion>Antipodean Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antioxidant</term>
<term>Double blind study</term>
<term>Mitochondria</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Placebo</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Etude double insu</term>
<term>Placebo</term>
<term>Mitochondrie</term>
<term>Antioxydant</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double-blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Nouvelle-Zélande</li>
<li>Royaume-Uni</li>
</country>
<settlement><li>Sydney</li>
</settlement>
</list>
<tree><country name="Nouvelle-Zélande"><noRegion><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name>
</noRegion>
<name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name>
<name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name>
<name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name>
<name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name>
<name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name>
</country>
<country name="Australie"><noRegion><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name>
</noRegion>
<name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002828 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002828 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= Pascal:10-0413289 |texte= A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQ as a Disease-Modifying Therapy in Parkinson's Disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |